- Home
- BYFC vs ESLA Comparison
BYFC vs ESLA Comparison
Compare BYFC & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BYFC | ESLA |
|---|---|---|
| Founded | 1946 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.7M | 60.9M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | BYFC | ESLA |
|---|---|---|
| Price | $7.79 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 2.3K | ★ 172.5K |
| Earning Date | 04-30-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $184,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.71 | N/A |
| 52 Week Low | $5.51 | $0.78 |
| 52 Week High | $8.85 | $3.15 |
Technical Indicators
Market Signals| Indicator | BYFC | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 50.31 | 68.78 |
| Support Level | $7.17 | $1.48 |
| Resistance Level | $7.93 | $2.18 |
| Average True Range (ATR) | 0.10 | 0.20 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 75.34 | 68.47 |
Price Performance
Historical ComparisonAbout BYFC Broadway Financial Corporation
Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank's business consists of deposits from the general public and using such deposits, together with borrowings and other funds, to make mortgage loans secured by residential properties and commercial real estate. Its deposits consist of passbook savings accounts, checking accounts, and negotiable order of withdrawal accounts, money market accounts and fixed-term certificates of deposit. The revenue is derived from interest income on loans and investments.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.